KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Goodwill & Intangibles: 2009-2019

Historic Goodwill & Intangibles for Arbutus Biopharma (ABUS) over the last 4 years, with Jun 2019 value amounting to $66.3 million.

  • Arbutus Biopharma's Goodwill & Intangibles fell 18.26% to $66.3 million in Q2 2019 from the same period last year, while for Jun 2019 it was $66.3 million, marking a year-over-year decrease of 18.26%. This contributed to the annual value of $66.3 million for FY2018, which is 20.12% down from last year.
  • According to the latest figures from Q2 2019, Arbutus Biopharma's Goodwill & Intangibles is $66.3 million, which was down 0.00% from $66.3 million recorded in Q1 2019.
  • Arbutus Biopharma's 5-year Goodwill & Intangibles high stood at $546.1 million for Q2 2015, and its period low was $66.3 million during Q3 2018.
  • Its 3-year average for Goodwill & Intangibles is $88.4 million, with a median of $82.1 million in 2017.
  • Data for Arbutus Biopharma's Goodwill & Intangibles shows a maximum YoY plummeted of 75.97% (in 2016) over the last 5 years.
  • Over the past 5 years, Arbutus Biopharma's Goodwill & Intangibles (Quarterly) stood at $515.2 million in 2015, then tumbled by 75.97% to $123.8 million in 2016, then tumbled by 32.95% to $83.0 million in 2017, then declined by 20.12% to $66.3 million in 2018, then fell by 18.26% to $66.3 million in 2019.
  • Its Goodwill & Intangibles was $66.3 million in Q2 2019, compared to $66.3 million in Q1 2019 and $66.3 million in Q4 2018.